What Semax is
Semax is an ACTH-fragment-derived neuropeptide analog discussed in cognition, stress-response, and neuroprotection conversations.
Semax is grouped under Longevity + Skin / Endogenous / Biology on PeptideFactCheck because it gets attention as a nootropic peptide that sounds more scientific than common supplement language.
The useful starting point is to separate the molecule itself from the internet story around it. It gets attention as a nootropic peptide that sounds more scientific than common supplement language.
Why people keep looking it up
It gets attention as a nootropic peptide that sounds more scientific than common supplement language.
Semax is an ACTH-fragment-derived neuropeptide analog discussed in cognition, stress-response, and neuroprotection conversations.
Semax tends to stay in the conversation because it touches a familiar public theme: neuropeptide analog, cognitive interest, and stress-response signaling. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Human and preclinical neuropeptide literature exists, but certainty remains limited.
There is human literature, but most modern online claims still outrun the quality and context of the evidence.
Mechanistic and preclinical neurobiology drive much of the interest.
Why this page carries the current tier: Human and preclinical neuropeptide literature exists, but certainty remains limited.
The current seed trail for Semax is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Region-specific use history and online enthusiasm do not replace clear modern regulatory or high-quality evidence review.
Semax is not FDA-approved in the current seed set and should not be presented as a mainstream regulated medicine.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Semax. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Semax is CID 9811102. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 9811102
- Formula
- C37H51N9O10S
- Molecular weight
- 813.9
- InChIKey
- AFEHBIGDWIGTEH-AQRCPPRCSA-N
Matched synonyms include Semax, 80714-61-0, ACTH (4-7), Pro-Gly-Pro-, I5FAL2585H, ACTH (4-7), prolyl-glycyl-proline-, Pro-gly-pro-acth (4-7), RefChem:56007, MEHFPGP.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Semax returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for Semax returns 327 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.